Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis YoY Growth in the U.S.: 78.0% in Q3 2026, down 30.0 pts from a year earlier.
Latest, Q3 2026
78.0%
Period ended Sep 30, 2026
Change on a year earlier
-30.0 pts
108.0% in Q3 2025
History
10 quarters
Since Q2 2024
Sources
10
Documents cited below
Where the Q3 2026 figure comes from
“|| Scemblix | Oncology | Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation | 414 | 78 | 179 | 43 | 46 | 593 | 66 | 67”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | YoY Growth in the U.S. (% USD / cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 78.0% | -30.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 93.0% | +11.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 86.0% | +11.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 88.0% | +28.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 108.0% | +55.0 pts | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 82.0% | +47.0 pts | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 75.0% | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 60.0% | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
| Q3 2024 | Sep 30, 2024 | 53.0% | – | Novartis Form 6-K (0001370368-24-000022) ↗ |
| Q2 2024 | Jun 30, 2024 | 35.0% | – | Novartis Form 6-K (0001370368-24-000019) ↗ |
Cite this data
StockData. (2026). Novartis YoY Growth in the U.S. (%), quarterly Q2 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix-us-yoy-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.